Inotrem Announces Enrollment of First Patient in its Phase IIb ASTONISH Trial for Nangibotide in the Treatment of Septic Shock
21.11.2019 10:00:00 EET | Business Wire | Press release
Inotrem S.A., a biotechnology company specializing in immunotherapy for acute inflammatory syndromes, through its knowledge of the TREM-1 pathway biology, announced today it has initiated its Phase IIb ASTONISH trial to evaluate nangibotide in the treatment of septic shock and has enrolled the first patient in the trial.
Nangibotide is a TREM-1 inhibitor peptide with the potential to restore appropriate inflammatory response, vascular function, and improve post septic shock survival. Septic shock is the ultimate complication of sepsis. The incidence of septic shock continuously raises and mortality remains elevated (35%) in developed countries. There is currently no specific therapy approved for this indication besides antibiotics and supportive treatment. Inotrem’s therapeutic solution has the potential to become the first mechanism-based treatment for septic shock. Nangibotide in septic shock has been granted the fast track status in September 2019 by the FDA and the PRIME status in 2017 by the EMA.
The Phase IIb ASTONISH study aims to demonstrate the efficacy of nangibotide and bring a medically relevant proof of clinical activity in septic shock patients. In addition, this global multicentric study intends to validate a personalized medicine approach using soluble TREM-1 as potential companion diagnostic test to identify patients more likely to benefit from nangibotide treatment. The study will be conducted in 48 clinical sites across 5 European countries and the United States and will enroll a total number of 450 patients.
Jean-Jacques Garaud, CEO of Inotrem, said: “The ASTONISH trial is a Phase III enabling trial and we expect that it will generate important insights about nangibotide’s clinical activity and our personalized medicine approach in septic shock. We are enthusiastic about this study and Inotrem’s capacity to bring a first in class product in an area with major unmet medical need and to patients who today have no access to any approved treatment”.
With nangibotide, Inotrem has developed a novel approach of immunomodulation targeting the TREM-1 pathway which has the potential to address, beyond septic shock, several others acute inflammatory syndromes for which there is a major and today unsatisfied therapeutic need. Based on its its extensive knowledge of the TREM-1 pathway biology, Inotrem has aso launched a new program to expand its TREM-1 franchise into chronic inflammatory diseases
About Inotrem
Inotrem S.A. is a biotechnology company specialized in immunotherapy for acute and chronic inflammatory syndromes. The company has developed a new concept of immunomodulation that targets the TREM-1 pathway to control unbalanced inflammatory responses. The company was founded in 2013 by Dr. Jean-Jacques Garaud, a former head of research and early development at the Roche Group, Prof. Sébastien Gibot and Dr. Marc Derive. Inotrem is supported by leading European and North American investors.
www.inotrem.com
About Nangibotide
Nangibotide is the formulation of the active ingredient LR12, which is a 12 amino-acid peptide prepared by chemical synthesis. LR12 is a specific TREM-1 inhibitor, acting as a decoy receptor and interfering in the binding of TREM-1 and its ligand. In preclinical septic shock models, nangibotide was able to restore appropriate inflammatory response, vascular function, and improved animals’ survival post septic shock. Nangibotide in septic shock has been granted the fast track status in September 2019 by the FDA.
ASTONISH Study
The Efficacy, Safety and Tolerability of nangibotide in Patients with Septic Shock (ASTONISH) phase IIb trial is a Randomized, Double-blind, Placebo Controlled Dose Selection Study that will be performed Europe and the US. Four hundred and fifty patients are planned to be included in this study in 48 clinical sites. The study will compare the effect of nangibotide at two different doses versus standard of care.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191120005756/en/
Contact information
Media contact for Inotrem
Anne REIN
S&I
anne.rein@strategiesimage.com
+33 6 03 35 92 05
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Navan Unveils New Ways to Book, Expense, and Travel at Navigate Europe 202615.10.2026 17:30:00 EEST | Press release
Navan (NASDAQ: NAVN), the global AI-powered business travel and expense platform, unveiled a new set of capabilities and product updates at Navigate Europe, its flagship customer conference. The updates bring Navan into more workplace tools, expand card issuing to new currencies, and simplify guest reimbursement, all while giving businesses greater visibility and control. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261015250476/en/ “Business never stands still. Our customers are constantly expanding and expecting more value, which is why we continue to innovate and elevate every part of the employee experience,” said Michael Riegel, Chief Customer Officer at Navan. “We’ve spent years building the global technology infrastructure and expertise to make travel and expense work better. These new capabilities will support more users in more ways than ever before, all from one connected platform that moves as fast as they do.”
FlightSafety International to Deliver New Embraer E190-E2 Full-Flight Simulator to Azul Brazilian Airlines15.10.2026 17:05:00 EEST | Press release
FlightSafety International Inc. (FSI), the global leader in aviation training and simulation technology, today announced an agreement with Azul Brazilian Airlines to design and manufacture a new Embraer E190-300 (E190-E2) Level D Full-Flight Simulator. Anticipated for delivery in late 2027, the simulator will expand Azul’s pilot training capabilities at its training center in Campinas, São Paulo, Brazil. “Our partnership with Azul reflects a shared commitment to advancing aviation training and safety,” said Michele Posey, Executive Vice President, Sales, FlightSafety International. “This new simulator will provide Azul pilots with a highly realistic training environment that supports the development of critical skills and prepares them for the demands of commercial flight operations.” “This new simulator represents another important investment in Azul’s operational excellence and long-term growth strategy. Expanding our training capabilities ensures that we continue to prepare our pilo
Andersen Global Deepens Private Client Tax Capabilities with KTA Tax15.10.2026 16:30:00 EEST | Press release
Andersen Global broadens its private client tax capabilities through a Collaboration Agreement with KTA Tax, a Dublin-based tax practice that has advised individuals and families for nearly three decades. KTA Tax has advised private clients and their families since 1997, combining the personal approach of a boutique practice with deep technical knowledge of Irish taxation. Its services span transaction and tax planning, estate planning, investments and pensions, cross-border matters, Revenue interventions, employment tax, and annual personal tax compliance. “We have remained focused on one thing: providing clear, thoughtful tax advice that reflects the individual circumstances of our clients and their families,” said Lisa Cantillon, CEO of KTA Tax. “Collaborating with Andersen Global is an important step for KTA Tax, giving us an opportunity to build on that foundation while extending the resources available to the clients we serve.” “Private client work demands an understanding of mor
Sysco Awards Partner of the Year Award to Grid Dynamics15.10.2026 16:15:00 EEST | Press release
Grid Dynamics Holdings, Inc. (Nasdaq: GDYN) (“Grid Dynamics”) today announced that Sysco, the global foodservice distribution leader, has named the company its Partner of the Year. The recognition honors Grid Dynamics’ approach and expertise in bringing AI into Sysco’s technology and business operations. Sysco is the global leader in foodservice distribution, generating $84.6 billion in sales for its fiscal year ended June 27, 2026, and serving approximately 670,000 customer locations across 10 countries. The partnership began in 2024 with Grid Dynamics teams working alongside Sysco across product search and discovery, digital commerce, and AI-first software development. Grid Dynamics delivered a range of projects that made everyday work easier for Sysco's associates, enhanced the customer experience, and generated measurable business value. “What makes this partnership work is how closely our teams operate together,” said Ragnarok Rocha, Vice President, Digital Commerce and Customer S
The Outcome Economy at Work – New Research From Vertage15.10.2026 16:01:00 EEST | Press release
Three in four enterprises (74%) define significant work around outcomes, but only 15% are ready to deliver it consistently, according to new global research from HR tech leader Vertage. These ‘outcome-ready’ enterprises report higher customer satisfaction (91% vs. 67%), stronger delivery of strategic goals (86% vs. 65%) and faster conversion of opportunities into value (85% vs. 64%). They also have a cultural edge: 69% of their employees understand their contribution and can adapt how they work, compared with 34% elsewhere. "AI adoption no longer separates strong businesses from the rest. Outcome readiness does," said Edzard Overbeek, Group CEO of Vertage. "The strongest businesses organize people, partners and AI around a clear result, and they keep human judgment at the center." The study, The Outcome Economy at Work, draws on 800 enterprise decision-makers and 1,200 workers across six markets, plus in-depth interviews with senior leaders. Its central finding is clear: outcome-based
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom